Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q96K19: Variant p.Cys102Arg

E3 ubiquitin-protein ligase RNF170
Gene: RNF170
Feedback?
Variant information Variant position: help 102 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Cysteine (C) to Arginine (R) at position 102 (C102R, p.Cys102Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In SPG85. Any additional useful information about the variant.


Sequence information Variant position: help 102 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 258 The length of the canonical sequence.
Location on the sequence: help YTDMYCPICLHQASFPVETN C GHLFCGACIIAYWRYGSWLG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         YTDMYCPICLHQASFPVETNCGHLFCGACIIAYWRYGSWLG

Mouse                         YTEMYCPICLHQASFPVETNCGHLFCGSCIIAYWRYGSWLG

Bovine                        YTDMYCPICLHQASLPVETNCGHLFCGTCIVAYWRYGSWLG

Xenopus laevis                YSDMTCPVCLQQATFPVETNCGHLFCGSCIIAYWRYGTWLG

Xenopus tropicalis            YSDMTCPVCLQQATFPVETNCGHLFCGSCIIAYWRYGSWLG

Zebrafish                     YSDMSCPVCLQQAVLPVETNCGHLFCGSCIIAYWRYGTWLG
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 258 E3 ubiquitin-protein ligase RNF170
Topological domain 46 – 201 Cytoplasmic
Zinc finger 87 – 130 RING-type
Alternative sequence 97 – 132 PVETNCGHLFCGACIIAYWRYGSWLGAISCPICRQT -> MHLLPLDSSSTLTCTVPSACTKPPSRWRPTVDIFFV. In isoform 4.
Mutagenesis 102 – 102 C -> S. Complete loss of E3 ligase activity; when associated with A-104.
Mutagenesis 104 – 104 H -> A. Complete loss of E3 ligase activity; when associated with S-102.



Literature citations
Bi-allelic variants in RNF170 are associated with hereditary spastic paraplegia.
Wagner M.; Osborn D.P.S.; Gehweiler I.; Nagel M.; Ulmer U.; Bakhtiari S.; Amouri R.; Boostani R.; Hentati F.; Hockley M.M.; Hoelbling B.; Schwarzmayr T.; Karimiani E.G.; Kernstock C.; Maroofian R.; Mueller-Felber W.; Ozkan E.; Padilla-Lopez S.; Reich S.; Reichbauer J.; Darvish H.; Shahmohammadibeni N.; Tafakhori A.; Vill K.; Zuchner S.; Kruer M.C.; Winkelmann J.; Jamshidi Y.; Schuele R.;
Nat. Commun. 10:4790-4790(2019)
Cited for: VARIANT SPG85 ARG-102; INVOLVEMENT IN SPG85;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.